Autoimmune hepatitis (AIH) is a chronic, progressive inflammatory liver disease characterized by circulating autoantibodies and elevated serum globulin levels. If left untreated, AIH may progress to chronic liver disease and cirrhosis and/or death [1]. A subgroup of patients, i.e., ∼10% have variant forms of AIH characteristics of primary biliary cholangitis (PBC), a rare cholestatic liver disease characterized by T-lymphocyte-mediated attack on small intralobular bile ducts or primary sclerosing cholangitis (PSC), another chronic progressive disorder of unknown etiology that is characterized by inflammation, fibrosis, and stricturing of medium and large ducts in the intrahepatic and/or extrahepatic biliary tree [2].
